600143.SS

The company's capital structure is characterized by a debt-to-equity ratio of 1.33, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.17, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. Free cash flow is negative at -90.19 million CNY, which may signal pressure on liquidity and the need for external financing or operational improvements. Profitability metrics show a return on equity (ROE) of 5.91% and a return on assets (ROA) of 1.79%. These figures are below the typical thresholds for strong performance in the Commodity Chemicals industry, which often requires ROE above 10% and ROA above 5% to be considered competitive. The company's operating income of 1.35 billion CNY and net income of 1.15 billion CNY reflect a relatively narrow margin, which may be influenced by high input costs or pricing pressures in the industry. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment or geographic breakdown in the financial data suggests a need for further transparency to assess risk and growth potential. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the capital expenditure of -2.33 billion CNY indicates a significant investment in infrastructure or expansion, which could support future growth. Analysts have provided a mean price target of 23.15 CNY, with a median of 23.15 CNY, suggesting a generally positive outlook, though the range from 21.30 to 25.00 CNY indicates some variability in expectations. Risk factors include a medium liquidity risk, as the company's net cash is negative after subtracting total debt. This could limit its ability to meet short-term obligations without additional financing. The dilution risk is assessed as low, with no significant dilution expected in the near term. However, the company's reliance on debt financing and the potential for further borrowing could introduce future dilution risks. Recent events include the publication of the latest financial data, which provides a snapshot of the company's current financial health. No recent filings or transcripts were provided in the input data, so the narrative is based on the most recent financial snapshot. Analysts have issued a mean recommendation of 1.60, indicating a generally positive outlook, with two strong-buy and three buy ratings, and no hold or sell ratings.